Subscribe to RSS
15 December 2011 (online)
pSivida is committed to the development of drug delivery products in the healthcare sector, initially in ophthalmology and oncology. pSivida has revenues from marketed products having developed the only two FDA approved sustained release back of the eye treatments for chronic eye disease and are licensed to Bausch & Lomb. Significant near-term revenues are expected from a diversified late-stage product portfolio including a next generation product licensed to Alimera Sciences for the treatment of Diabetic Macular Edema and Pfizer for all other ophthalmic applications. pSivida also owns the right to develop and commercialize a new biomaterial, nanostructured porous silicon (BioSilicon™), for multiple potential applications in healthcare with a core focus on drug delivery. pSivida’s largest shareholder and strategic partner is Pfizer. QinetiQ (one of the largest R&D institutions in Europe) is a top five shareholder. pSivida has a primary listing on the NASDAQ stock exchange (PSDV) and is also listed on the Frankfurt (PSI) and Australian (PVA) stock exchanges.